With the guidance of Oriel STAT A MATRIX, our customer successfully addressed the FDA’s concerns with limited impact to its reputation and bottom line.
When our customer, a leading medical device manufacturer, received a FDA 483 Warning Letter from the U.S. FDA, its leaders knew they needed a strategic plan to respond quickly and properly if they were to successfully implement remediative actions to close out the letter and reopen their new product applications at the agency.
The company chose Oriel STAT A MATRIX to help its leadership navigate through this FDA compliance challenge because of our long, successful history working with both the FDA and other leading companies in the sector. We provided our customer with FDA consultants to plan and work through the remediation effort. Together, we developed and implemented an effective action plan that both rectified the FDA compliance violations and established sustainable changes that addressed the FDA’s concerns and enhanced the overall business quality functions.
What is a FDA 483 Warning Letter
No one wants to receive a Form 483 and/or warning letter from the U.S. Food and Drug Administration (FDA). Officially, the FDA Form 483 is referred to as “Notice of Inspectional Observations.” The 483 is issued by an FDA field investigator after an on-site inspection; it lists deficiencies in your quality system. The observations contained in every Form 483 are based on the inspector’s evaluation of your operation and on his or her interpretation of the regulations and how they relate to your operational good manufacturing practice (GMP) quality system.
The field inspector will submit the finalized 483 to his/her superiors, and based on the severity of the findings, an FDA warning letter may be issued to your firm.
What do I need to do if I receive a FDA 483 or Warning Letter?
You must respond to the FDA 483 warning letter in a timely manner and identify your plan to implement a corrective aiction program to remedy the findings. A detailed response to each finding will also be necessary for each item addressed. The quality and promptness of our response to this letter is extremely important.
Often, the FDA will require a company who receives a 483 warning letter to hire a consultant to assist in the resolution of the findings. Even if the FDA has not made this mandatory as a result of your particular warning letter, the FDA looks at this voluntary action as a commitment by your company to bring it back into compliance.
How can Oriel STAT A MATRIX help me recover from a FDA 483 or Warning Letter?
Oriel STAT A MATRIX can assist you in preparing an effective response to an FDA 483 and/or warning letter. We can provide you with direction and hands-on assistance in developing and implementing a remediation plan to ensure your GMP quality system will be in compliance with the FDA regulations. We can:
- Analyze the findings of the FDA 483 and/or warning letter.
- Develop a plan of action to remedy any deficiencies.
- Develop a timeline for implementation.
- Lead and/or assist in implementation of the plan.
- Act as an interim management representative.
- Be a resource to answer questions from you or the FDA during your efforts to correct the noted deficiencies.
If you have received a 483, warning letter, or need immediate assistance during an FDA inspection, please call 1.800.472.6477.